Sarepta Therapeutics, Inc. Share Price

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 22/06/2024 am IST 5-day change 1st Jan Change
160.7 USD +30.14% Intraday chart for Sarepta Therapeutics, Inc. +30.84% +66.67%
Sales 2024 * 2B 167B Sales 2025 * 3.06B 255B Capitalization 15.19B 1,269B
Net income 2024 * 347M 28.99B Net income 2025 * 1.01B 84.46B EV / Sales 2024 * 7.06 x
Net cash position 2024 * 1.05B 88.13B Net cash position 2025 * 2.46B 206B EV / Sales 2025 * 4.16 x
P/E ratio 2024 *
45.4 x
P/E ratio 2025 *
14 x
Employees 1,314
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.03%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Sarepta Therapeutics, Inc.

1 day+0.64%
1 week+30.84%
Current month+23.76%
1 month+24.47%
3 months+28.64%
6 months+77.10%
Current year+66.67%
More quotes
1 week
115.74
Extreme 115.74
173.25
1 month
109.91
Extreme 109.91
173.25
Current year
91.34
Extreme 91.3439
173.25
1 year
55.25
Extreme 55.25
173.25
3 years
55.25
Extreme 55.25
173.25
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 26/17/26
Director of Finance/CFO 48 01/15/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 61 26/17/26
Chairman 71 31/09/31
Director/Board Member 65 02/15/02
More insiders
Date Price Change Volume
21/24/21 160.7 +30.14% 15,011,554
20/24/20 123.5 +5.09% 2,155,138
18/24/18 117.5 +0.59% 1,467,811
17/24/17 116.8 -4.89% 1,422,151
14/24/14 122.8 -1.73% 1,000,340

Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST

More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
160.7 USD
Average target price
193.4 USD
Spread / Average Target
+20.31%
Consensus